title: Blood transcript analysis and metastatic recurrent small bowel carcinoid management.
abstract: BACKGROUND
  Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA) measurement.
  
  
  METHODS
  We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index) to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and (68)Ga-DOTA-PET/CT in a patient with NET.
  
  
  CONCLUSIONS
  Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests this parameter may also have utility as an index of therapeutic efficacy.
authors.affiliation: Wren Laboratories, 35 NE Industrial Road, Branford, CT 06405, USA. imodlin@optonline.net.
authors.forename: Irvin M
authors.initials: IM
authors.lastname: Modlin
authors.forename: Ignat
authors.initials: I
authors.lastname: Drozdov
authors.forename: Lisa
authors.initials: L
authors.lastname: Bodei
authors.forename: Mark
authors.initials: M
authors.lastname: Kidd
mesh_terms: D002276:Carcinoid Tumor / Q000097:blood / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D053379:Chromogranin A / Q000097:blood / Q000235:genetics; D006801:Humans; D007414:Intestinal Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000235:genetics; D018358:Neuroendocrine Tumors / Q000097:blood / Q000235:genetics* / Q000473:pathology*; D016133:Polymerase Chain Reaction; D049268:Positron-Emission Tomography
chemical_list: D053379:Chromogranin A
references.citation: Ann Surg. 2010 Nov;252(5):850-6
references.pmid: 21037441
references.citation: Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):72-82
references.pmid: 21927931
references.citation: Endocrinol Metab Clin North Am. 2011 Mar;40(1):111-34, viii
references.pmid: 21349414
references.citation: Endocr Relat Cancer. 2014 Aug;21(4):615-28
references.pmid: 25015994
references.citation: Eur J Endocrinol. 2013 Jan 17;168(2):185-93
references.pmid: 23132699
references.citation: Lancet Oncol. 2008 Jan;9(1):61-72
references.pmid: 18177818
references.citation: Ann Clin Biochem. 2007 May;44(Pt 3):300-7
references.pmid: 17456301
references.citation: J Clin Oncol. 2011 Mar 1;29(7):934-43
references.pmid: 21263089
references.citation: Neuroendocrinology. 2013;98(1):16-30
references.pmid: 23446227
references.citation: Ann Surg. 2010 Feb;251(2):307-10
references.pmid: 20010089
references.citation: J Natl Cancer Inst. 2008 Sep 17;100(18):1282-9
references.pmid: 18780869
references.citation: PLoS One. 2013 May 15;8(5):e63364
references.pmid: 23691035
references.citation: Clin Gastroenterol Hepatol. 2008 Jul;6(7):820-7
references.pmid: 18547872
references.citation: Nucl Med Commun. 2011 Aug;32(8):731-7
references.pmid: 21633314
references.citation: World J Surg. 2004 Sep;28(9):890-5
references.pmid: 15593463
references.citation: Clin Chem. 2004 Sep;50(9):1634-9
references.pmid: 15247155
references.citation: Ann Surg Oncol. 2009 Feb;16(2):487-98
references.pmid: 19050963
references.citation: Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):33-41
references.pmid: 17382264
references.citation: Neuroendocrinology. 2010;91(1):101-9
references.pmid: 19996582
references.citation: Endocr Relat Cancer. 2012 Sep 14;19(5):R163-85
references.pmid: 22645227
references.citation: Ann Surg Oncol. 2007 Feb;14(2):780-5
references.pmid: 17146740
references.citation: Biomarkers. 2012 Mar;17(2):186-91
references.pmid: 22303881
references.citation: J Nucl Med. 2012 Aug;53(8):1207-15
references.pmid: 22782315
references.citation: Cancer. 1999 Sep 1;86(5):858-65
references.pmid: 10463986